



Welchol[®] (colesevelam hydrochloride) – First time generic

- On July 17, 2018, [Glenmark Pharmaceuticals announced](#) the FDA approval of an [AB-rated](#) generic version of Daiichi Sankyo's [Welchol[®] \(colesevelam hydrochloride\)](#) packets for oral suspension.
- Welchol is a bile acid sequestrant indicated as an adjunct to diet and exercise to:
 - Reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia (Fredrickson Type IIa) as monotherapy or in combination with a hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin).
 - Reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia as monotherapy or in combination with a statin after failing an adequate trial of diet therapy.
 - Improve glycemic control in adults with type 2 diabetes mellitus.
- Colesevelam hydrochloride is also available generically as an oral tablet and carries the same indications.
- According to IQVIA data, Welchol packets for oral suspension, 1.875 grams/packet and 3.75 grams/packet, achieved annual sales of approximately \$73.0 million ending May 2018.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.